Correlation of intensity of MT-I/II expression with Ki-67 and MCM-2 proteins in invasive ductal breast carcinoma

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 3027-3033

  Wojnar, Andrzej ^a   Pula, Bartosz ^b   Piotrowska, Aleksandra ^b   Jethon, Aleksandra ^b   Kujawa, Krzysztof ^c   Kobierzycki, Christopher ^b   Rys, Janusz ^d   Podhorska Okolow, Marzena ^b   Dziegiel, Piotr ^a,b,e  

^a Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c INSTITUTE FOR AGRICULTURAL AND FOREST ENVIRONMENT   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Breast cancer; Ki 67; MCM 2; Metallothionein; MT I II

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; KI 67 ANTIGEN; METALLOTHIONEIN I; METALLOTHIONEIN II; MINICHROMOSOME MAINTENANCE PROTEIN 2; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE DUCTAL BREAST CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA, DUCTAL; CELL CYCLE PROTEINS; FEMALE; HUMANS; KI-67 ANTIGEN; METALLOTHIONEIN; MIDDLE AGED; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS;

EID: 80051649587     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer Statistics. CA Cancer J Clin 58: 71-96, 2008.
3. Yerushalmi R, Woods R, Ravdin PM, Hayes MM and Gelmon KA: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183, 2010.
4. Dziȩgiel P: Expression of metallothioneins in tumor cells. Pol J Pathol 55: 3-12, 2004.
5. Pedersen MØ, Larsen A, Stoltenberg M and Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 44: 29-64, 2009.
6. Cherian MG and Apostolova MD: Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol 46: 347-356, 2000.
7. Koropatnick J, Kloth DM, Kadhim S, Chin JL and Cherian MG: Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line. J Pharmacol Exp Ther 275: 1681-1687, 1995. (Pubitemid 26129961)
8. Deng DX, Cai L, Chakrabarti S and Cherian MG: Increased radiation-induced apoptosis in mouse thymus in the absence of metallothionein. Toxicology 134: 39-49, 1999. (Pubitemid 29245097)
9. Cai L and Cherian MG: Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper- or cadmium- metallothioneins. Toxicol Lett 136: 193-198, 2003.
10. Surowiak P, Materna V, Maciejczyk A, Pudełko M, Markwitz E, Spaczyński M, Dietel M, Zabel M and Lage H: Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450: 279-285, 2007. (Pubitemid 46376562)
11. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Tarkowski R, Wlodarska I, Spytkowska B, Gisterek I, Matkowski R and Kornafel J: Prognostic significance of nuclear and cytoplasmic expression of metallothioneins as related to proliferative activity in squamous cell carcinomas of oral cavity. Histol Histopathol 23: 843-851, 2008.
12. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Trakowski R, Spytkowska B, Matkowski R and Kornafel J: Correlation of metallothionein expression with clinical progression of cancer in oral cavity. Anticancer Res 29: 589-596, 2009.
13. Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E and Zabel M: Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res 27: 335-342, 2007. (Pubitemid 46363351)
14. Dziegiel P, Forgacz J, Suder E, Surowiak P, Kornafel J and Zabel M: Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol 18: 401-407, 2003. (Pubitemid 36362057)
15. Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A and Zabel M: Prognostic significance of augmented metallothionein expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol 20: 83-89, 2005. (Pubitemid 40028986)
16. Jin R, Huang J, Tan PH and Bay BH: Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res 10: 74-79, 2004. (Pubitemid 38915598)
17. Bay BH, Jin R, Huang J and Tan PH: Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med 231: 1516-1521, 2006.
18. Yap X, Tan HY, Huang J, Lai Y, Yip GW, Tan PH and Bay BH: Over-expression of metallothionein predicts chemoresistance in breast cancer. J Pathol 217: 563-570, 2009.
19. Giaginis C, Vgenopoulou S, Vielh P and Theocharis S: MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histol Histopathol 25: 351-370, 2010.
20. Kearsey SE and Labib K: MCM proteins: evolution, properties and role in DNA replication. Biochim Biophys Acta 1398: 113-136, 1998.
21. Ritzi M and Knippers R: Initiation of genome replication: assembly and disassembly of replication-competent chromatin. Gene 245: 13-20, 2000. (Pubitemid 30125359)
22. Laskey RA and Madine MA: A rotary pumping model for helicase function of MCM proteins at a distance from replication forks. EMBO Rep 4: 26-30, 2003. (Pubitemid 36305373)
23. Todorov IT, Attaran A and Kearsey SE: BM28, a human member of the MCM2-3-5 family, is displaced from chromatin during DNA replication. J Cell Biol 129: 1433-1445, 1995.
24. Romanowski P and Madine MA: Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc 6 and ORC. Trends Cell Biol 7: 9-10, 1997. (Pubitemid 27056377)
25. Stoeber K, Mills AD, Kubota Y, Krude T, Romanowski P, Marheineke K, Laskey RA and Williams GH: Cdc6 protein causes premature entry into S-phase in a mammalian cell-free system. EMBO J 17: 7219-7229, 1998. (Pubitemid 29002691)
26. Wojnar A, Kobierzycki C, Krolicka A, Pula B, Podhorska-Okolow M and Dziegiel P: Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. Folia Histochem Cytobiol 48: 442-446, 2010.
27. Shetty A, Loddo M, Fanshawe T, Prevost AT, Sainsbury R, Williams GH and Stoeber K: DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Br J Cancer 93: 1295-1300, 2005. (Pubitemid 41679416)
28. Gonzalez MA, Pinder SE, Callagy G, Vowler SL, Morris LS, Bird K, Bell JA, Laskey RA and Coleman N: Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 21: 4306-4313, 2001.
29. Nowinska K and Dziegiel P: The role of MCM proteins in cell proliferation and tumorigenesis. Postepy Hig Med Dosw 64: 627-635, 2010.
30. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, Lafitte JJ and Sculier JP: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91: 2018-2025, 2004. (Pubitemid 40128768)
31. Czyzewska J, Guzinska-Ustymowicz K, Pryczynicz A, Kemona A and Bandurski R: Immunohistochemical evaluation of Ki-67, PCNA and MCM-2 proteins proliferation index (PI) in advanced gastric cancer. Folia Histochem Cytobiol 47: 289-296, 2009.
32. Tavassoli FA and Devilee P (eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, pp. 18-19, 2003.
33. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
34. Reena RM, Mastura M and Siti-Aishah MA: Minichromosome maintenance protein 2 is a reliable proliferative marker in breast carcinoma. Ann Diagn Pathol 12: 340-343, 2008.
35. Bier B, Douglas-Jones A, Tötsch M, Dockhorn-Dworniczak B, Böcker W, Jasani B and Schmid KW: Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions. Breast Cancer Res Treat 30: 213-221, 1994. (Pubitemid 24262116)
36. Ioachim E, Kamina S, Demou A, Kontostolis M, Lolis D and Agnantis NJ: Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res 19: 2133-2139, 1999. (Pubitemid 29392783)
37. Ioachim E, Tsanou E, Briasoulis E, Batsis Ch, Karavasilis V, Charchanti A, Pavlidis N and Agnantis NJ: Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 12: 111-119, 2003.
38. Gomulkiewicz A, Podhorska-Okolow M, Szulc R, Smorag Z, Wojnar A, Zabel M and Dziegiel P: Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers. Folia Histochem Cytobiol 48: 242-248, 2010.
39. Abdel-Mageed A and Agrawal KC: Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 4: 199-207, 1997. (Pubitemid 127667116)
40. Lim D, Jocelyn KM, Yip GW and Bay BH: Silencing the metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells. Cancer Lett 276: 109-117, 2008.
41. Tai SK, Tan OJ, Chow VT, Jin R, Jones JL, Tan PH, Jayasurya A and Bay BH: Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol 163: 2009-2019, 2003.
42. Jin R, Chow VT, Tan PH, Dheen ST, Duan W and Bay BH: Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 23: 81-86, 2002. (Pubitemid 34213555)